Work

Abstract CT299: Dirozalkib versus crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): Results from the multicenter, randomized, open-label phase 3 trial

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct299

Authors: Ying Liu, Xiangjiao Meng, Yan Yu, Jianhua Chen, Runxiang Yang, Laiyu Liu, Yanqiu Zhao, Ruifen Tian, Dianming Li, Ruiling Ning, Qingshan Li, Guowu Wu, Li Wang, Xianghui Duan, Xuejie Guo, Yan Hu, Weili Liu, Haifeng Liu

Institutions: Jilin Province Tumor Hospital, Shandong Tumor Hospital, Shandong First Medical University, Harbin Medical University, Hunan Cancer Hospital, Nanfang Hospital, Southern Medical University, Zhengzhou University, Henan Cancer Hospital, Shanxi Provincial Cancer Hospital, First Affiliated Hospital of Bengbu Medical College, Guangxi Medical University, Tumor Hospital of Guangxi Medical University, Chengde Medical University, Affiliated Hospital of Chengde Medical College, Meizhou City People's Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154705745

Cites:

Cited by:

Related to: